Drusolv Therapeutics

11:15 AM - 11:30 AM, Tuesday, June 4,2019 ・ SuS - Hall E, Booth 3971, Level 200
Clinical-stage drug development company that is formulating high-dose statin, a medication to lower cholesterol levels, for early intervention in Age-related Macular Disease, which causes blindness. Having completed a proof-of-concept trial, the company will continue with Phase II and III clinical trials with the eventual goal of selling statin as a drug treatment to ophthalmologists, who would then prescribe and distribute the drug to patients.
Speaker
photo
CEO
Drusolv Therapeutics